862801-50-1

Upstream product

• 1866-39-3 4-methylcinnamic acid 
• 20511-20-0 ethyl p-methylcinnamate 
• 943-89-5 (E)-3-(4-methoxyphenyl)acrylic acid 
• 53484-50-7 (E)-p-methoxy-cinnamyl alcohol 
• 24393-56-4 ethyl p-methoxycinnamate 
• 53484-50-7 p-methoxycinnamyl alcohol 
• 23855-31-4 4-(4-methoxyphenyl)-3-methyl-1,2,5-oxadiazole 2-oxide 
• 497845-94-0 3-(bromomethyl)-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide 

Downstream Products

• 862608-06-8 (4-(4-hydroxyphenyl)furoxan-3-yl)methanol 
• 862608-11-5 4-(4-hydroxyphenyl)furazan-3-carbonitrile 
• 862608-07-9 (4-(4-hydroxyphenyl)furazan-3-yl)methanol 
• 862608-10-4 4-(4-hydroxyphenyl)furoxan-3-carbonitrile 
• 862608-09-1 4-(4-hydroxyphenyl)furazan-3-carboxamide 
• 862608-08-0 4-(4-hydroxyphenyl)furoxan-3-carboxamide 
• 862801-52-3 ethyl (4-(4-hydroxymethyl)furazan-3-yl)phenyl carbonate 
• 862801-56-7 carbonic acid ethyl ester 4-[4-(hydroxyimino-methyl)-furazan-3-yl]-phenyl ester 
• 862801-51-2 ethyl (4-(3-hydroxymethyl)furoxan-4-yl)phenyl carbonate 
• 862801-54-5 4-(3-((tetrahydro-2H-pyran-2-yloxy)methyl)furazan-3-yl)phenol 
• 862801-53-4 4-(3-((tetrahydro-2H-pyran-2-yloxy)methyl)furoxan-4-yl)phenol 
• 862876-41-3 4-{4-[3-(1H-imidazol-4-yl)-propoxy]-phenyl}-2-oxy-furazan-3-carbonitrile 
• 862876-47-9 4-{4-[3-(1H-imidazol-4-yl)-propoxy]-phenyl}-furazan-3-carboxylic acid amide 
• 862876-46-8 4-{4-[3-(1H-imidazol-4-yl)-propoxy]-phenyl}-2-oxy-furazan-3-carboxylic acid amide 

Relevant academic research and scientific papers

Aurovertin B derivative and preparation method and application thereof

The invention relates to an aurovertin B derivative and a preparation method of the aurovertin B derivative, and application of the aurovertin B derivative in preparation of a medicine for treating triple-negative breast cancer. Compared with aurovertin B, the aurovertin B derivative disclosed by the invention has the advantages that the water solubility of the compound is improved, the bioavailability can be improved, and the preparation is convenient to prepare. Meanwhile, compared with aurovertin B, the aurovertin B derivative disclosed by the invention has the advantages that the derivative has obvious dose dependence, the toxicity of the compound to normal cells is reduced, and the druggability of the compound is improved. The aurovertin B derivative disclosed by the invention has a very strong inhibition effect on proliferation of triple-negative breast cancer cells, and the activity of the aurovertin B derivative is stronger than that of paclitaxel serving as a clinical drug.

Furoxans (Oxadiazole-4 N-oxides) with Attenuated Reactivity are Neuroprotective, Cross the Blood Brain Barrier, and Improve Passive Avoidance Memory

Nitric oxide (NO) mimetics and other agents capable of enhancing NO/cGMP signaling have demonstrated efficacy as potential therapies for Alzheimer's disease. A group of thiol-dependent NO mimetics known as furoxans may be designed to exhibit attenuated reactivity to provide slow onset NO effects. The present study describes the design, synthesis, and evaluation of a furoxan library resulting in the identification of a prototype furoxan, 5a, which was profiled for use in the central nervous system. Furoxan 5a demonstrated negligible reactivity toward generic cellular thiols under physiological conditions. Nonetheless, cGMP-dependent neuroprotection was observed, and 5a (20 mg/kg) reversed cholinergic memory deficits in a mouse model of passive avoidance fear memory. Importantly, 5a can be prepared as a pharmaceutically acceptable salt and is observed in the brain 12 h after oral administration, suggesting potential for daily dosing and excellent metabolic stability. Continued investigation into furoxans as attenuated NO mimetics for the CNS is warranted.

FUROXANS AS THERAPIES FOR NEURODEGENERATIVE DISORDERS

Furoxan compounds, compositions comprising the same, and methods of making and using the same, are described.

A class of 1, 2, 5 - oxadiazole - 2 oxide analogs, its preparation and use

The invention provides 1,2,5-oxadiazole-2 oxide analogue with a structure shown as general formula I, and a preparation method and an application thereof. The 1,2,5-oxadiazole-2 oxide analogue has the activity for resisting schistosome thioredoxin glutathione reductase, kills schistosome by blocking a normal redox equilibrium physiological metabolism process of schistosome cells, can be used as a drug lead for development of drugs for treating schistosomiasis, and provides novel means for preventing and treating schistosomiasis. The general formula I is shown in the description.

An expedient synthesis of new 2-(furoxan-3-yl)thiazolidin-4-one derivatives

A series of new biologically interesting furoxan-3-thiazolidinones have been synthesized via one-pot three-component reaction of furoxan aldehydes, anilines and mercaptoacetic acid. The multi-component reaction involves condensation of furoxan aldehyde with aniline to give imine; the formed imine undergoes nucleophilic addition with mercaptoacetic acid, followed by cyclisation with loss of H2O to obtain the desired products. All the synthesized compounds were well characterized using spectral techniques and confirmed by an X-ray crystal structure for one compound.

Furoxans (1,2,5-Oxadiazole- N -oxides) as novel no mimetic neuroprotective and procognitive agents

Furoxans (1,2,5-oxadiazole-N-oxides) are thiol-bioactivated NO-mimetics that have not hitherto been studied in the CNS. Incorporation of varied substituents adjacent to the furoxan ring system led to modulation of reactivity toward bioactivation, studied

Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents

The synthesis of several 1,2,5-oxadiazole-2-oxide (Furoxan) analogues is described herein. These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and antischistosomal activity.

Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis

Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we recently identified as inhibitors of thioredoxin glutathione reductase (TGR), a selenocysteine-containing flavoenzyme required by the parasite to maintain proper cellular redox balance. Through systematic evaluation of the core molecular structure of this chemotype, we define the essential pharmacophore, establish a link between the nitric oxide donation and TGR inhibition, determine the selectivity for this chemotype versus related reductase enzymes, and present evidence that these agents can be modified to possess appropriate drug metabolism and pharmacokinetic properties. The mechanistic link between exogenous NO donation and parasite injury is expanded and better defined. The results of these studies verify the utility of oxadiazole-2-oxides as novel inhibitors of TGR and as efficacious antischistosomal agents. 2009 American Chemical Society.

Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives

Synthesis and pharmacological characterisation of a series of compounds in which the oxime substructure present in imoproxifan was constrained in the pentatomic NO-donor furoxan ring, as well as their structurally related furazan analogues devoid of NO-do